IMR Press / FBE / Volume 9 / Issue 1 / DOI: 10.2741/E789

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Design, synthesis and use of peptoids in the diagnosis and treatment of cancer

Show Less
1 Signal Transduction in Cancer and Stem Cells Laboratory, Division of Cancer Biology and Inflammatory Disorder, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology (CSIR-IICB), 4 Raja S.C. Mullick Road Kolkata- 700032 and CN-06 Setor-V, Salt Lake, Kolkata-700091, India
2 Department of Microbiology, Barrackpore Rastraguru Surendranath College, 6 Riverside Road and 85 Middle Road, Barrackpore, Kolkata-700 120, India

*Author to whom correspondence should be addressed.

Academic Editors: Nevim Aygun, Siamak Tabibzadeh

Front. Biosci. (Elite Ed) 2017, 9(1), 102–109; https://doi.org/10.2741/E789
Published: 1 January 2017
Abstract

Genetic variations in cancer cells are the underpinning for the development of resistance and failure of the treatment by current anticancer drugs. Thus, an ideal drug must overcome failure of treatment and prevents development of drug resistance. There are a wide variety of emerging, easy to prepare and cost effective group of drugs that are collectively called peptoids or peptidomimetics. These new set of drugs exhibit distinct features including protease resistance, are non-immunogenic, do not hinder functionality and backbone polarity, and can adopt different conformations. These drugs have shown promise as diagnostic and therapeutic tools in a wide variety of diseases. Here, we discuss the recent advancement in the design and synthesis of peptoids and use of these drugs in the diganosis and treatment of a wide number of cancers of the lung, prostate, and breast.

Keywords
Peptoid
Cancer
Therapy
Diagnosis
Review
Share
Back to top